Predicted to contribute to cell adhesion molecule binding activity and signaling receptor binding activity. Involved in cellular response to interleukin-1 and cellular response to leptin stimulus. Localizes to the blood microparticle and cytoplasm. Biomarker of pancreatitis and pulmonary embolism. Human ortholog(s) of this gene implicated in cardiovascular system disease (multiple); congenital afibrinogenemia; and end stage renal failure. Orthologous to human FGB (fibrinogen beta chain); PARTICIPATES IN acenocoumarol pharmacodynamics pathway; alteplase pharmacodynamics pathway; aminocaproic acid pharmacodynamics pathway; INTERACTS WITH (RS)-amphetamine; 1-naphthyl isothiocyanate; 17beta-estradiol.
[Tetrachlorodibenzodioxin binds to AHR protein] which results in decreased expression of FGB mRNA, [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of FGB mRNA
Aspirin inhibits the reaction [Adenosine Diphosphate results in decreased secretion of FGB protein], Aspirin inhibits the reaction [thrombin receptor-activating peptide SFLLRNPNDKY analog results in increased secretion of FGB protein]
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGB mRNA
[CTH gene mutant form results in increased susceptibility to Acetaminophen] which results in increased expression of FGB protein, saikosaponin inhibits the reaction [Acetaminophen results in increased expression of FGB mRNA]
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGB mRNA
[pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of FGB mRNA, [pirinixic acid co-treated with PPARA] results in decreased expression of FGB mRNA
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGB mRNA
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Gene-Chemical Interaction Annotations
